[go: up one dir, main page]

MA28032A1 - Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc - Google Patents

Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Info

Publication number
MA28032A1
MA28032A1 MA28865A MA28865A MA28032A1 MA 28032 A1 MA28032 A1 MA 28032A1 MA 28865 A MA28865 A MA 28865A MA 28865 A MA28865 A MA 28865A MA 28032 A1 MA28032 A1 MA 28032A1
Authority
MA
Morocco
Prior art keywords
treatment
related disorders
cyclosporins
hcv related
modified cyclosporins
Prior art date
Application number
MA28865A
Other languages
English (en)
Inventor
Makoto Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28032A1 publication Critical patent/MA28032A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne ses cyclosporines sans activité immunosuppressive se liant à la cyclophiline (voir formules I, Ia ou II) comme définies dans le descriptif, qui possèdent des propriétés puissantes dans la prévention ou le traitement des infections par le virus de l'hépatite C.
MA28865A 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc MA28032A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds

Publications (1)

Publication Number Publication Date
MA28032A1 true MA28032A1 (fr) 2006-07-03

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28865A MA28032A1 (fr) 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Country Status (30)

Country Link
US (1) US7968518B2 (fr)
EP (2) EP1797892B1 (fr)
JP (1) JP4688806B2 (fr)
KR (1) KR101116968B1 (fr)
CN (1) CN1842343A (fr)
AU (2) AU2004268382A1 (fr)
BR (1) BRPI0414062B8 (fr)
CA (1) CA2537137C (fr)
CY (1) CY1110506T1 (fr)
DE (1) DE602004022061D1 (fr)
DK (1) DK1663287T3 (fr)
ES (1) ES2328361T3 (fr)
GB (1) GB0320638D0 (fr)
HK (1) HK1091732A1 (fr)
HR (1) HRP20090535T1 (fr)
IL (1) IL173909A (fr)
IS (1) IS2917B (fr)
MA (1) MA28032A1 (fr)
MX (1) MXPA06002394A (fr)
NO (1) NO20061479L (fr)
NZ (1) NZ545495A (fr)
PL (1) PL1663287T3 (fr)
PT (1) PT1663287E (fr)
RU (1) RU2389501C2 (fr)
SG (1) SG149063A1 (fr)
SI (1) SI1663287T1 (fr)
TN (1) TNSN06071A1 (fr)
TW (1) TWI342782B (fr)
WO (1) WO2005021028A1 (fr)
ZA (1) ZA200601550B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255275T3 (es) 1998-07-01 2006-06-16 Debiopharm S.A. Nueva ciclosporina con perfil de actividad mejorado.
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2573207C (fr) 2004-07-14 2013-04-16 Novartis Ag Utilisation d'une combinaison de cyclosporine et de peg interferons dans le traitement de l'hepatite c (hcv)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CN101773661B (zh) * 2004-10-01 2013-09-25 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
NZ554412A (en) 2004-10-01 2011-01-28 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
WO2006054801A1 (fr) 2004-11-22 2006-05-26 Astellas Pharma Inc. Nouveau peptide cyclique
WO2006071619A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc
EP1830870A1 (fr) * 2004-12-23 2007-09-12 Novartis AG Composes pour le traitement des infections virales par flaviviridae
BRPI0613142A2 (pt) * 2005-06-17 2010-12-21 Novartis Ag uso de sangliferina em hcv
WO2007041631A1 (fr) * 2005-09-30 2007-04-12 Scynexis, Inc. Derives d'arylalkyle et d'heteroarylalkyle de cyclosporine a utilises pour traiter et prevenir une infection virale
CA2623865A1 (fr) * 2005-09-30 2007-04-12 Scynexis, Inc. Procedes et compositions pharmaceutiques pour traiter et prevenir une infection par le virus de l'hepatite c
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
BRPI0617781A2 (pt) * 2005-10-26 2011-08-09 Astellas Pharma Inc compostos de peptìdeos cìclicos
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ES2361635T3 (es) 2006-05-19 2011-06-20 Scynexis, Inc. Ciclosporinas para el tratamiento y prevención de trastornos oculares.
CN101502196A (zh) * 2006-06-02 2009-08-05 克洛德·安妮·佩里西恩 激活电子的管理
MX2009003743A (es) * 2006-10-12 2009-06-18 Novartis Ag Uso de ciclosporinas modificadas.
WO2008069917A2 (fr) * 2006-11-20 2008-06-12 Scynexis, Inc. Nouveaux peptides cycliques
CA2674296C (fr) * 2007-01-04 2015-11-24 Debiopharm Sa Cyclosporine non immunosuppressive pour le traitement de la dystrophie musculaire congenitale d'ullrich
US8603975B2 (en) * 2007-05-02 2013-12-10 Astellas Pharma Inc. Cyclic peptide compounds
EP2193807A4 (fr) * 2007-08-24 2012-09-12 Univ Sapporo Medical Protéine de liaison à la cyclosporine a
CN102083852A (zh) * 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
KR20110045032A (ko) * 2008-07-30 2011-05-03 이소테크니카 파마 인크. 비면역억제성 사이클로스포린 유사체 분자
CA2738280A1 (fr) * 2008-09-24 2010-04-01 Astellas Pharma Inc. Compose peptidique et son procede de production
EA020896B1 (ru) * 2008-11-06 2015-02-27 Дебио Решерш Фармасетик С.А. Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
CA2751210C (fr) 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Analogues de la cyclosporine pour prevenir ou traiter une infection par l'hepatite c
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
WO2011063076A1 (fr) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
JP2013513595A (ja) 2009-12-09 2013-04-22 サイネクシス，インコーポレーテッド 新規環状ペプチド
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
KR20140035305A (ko) 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
BR112013013166A2 (pt) 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
PL2651965T3 (pl) 2010-12-15 2019-04-30 Contravir Pharmaceuticals Inc Cząsteczki analogów cyklosporyny modyfikowane w aminokwasach 1 i 3
MX2013011256A (es) 2011-03-31 2013-10-17 Novartis Ag Alisporivir para el tratamiento de la infeccion por el virus de hepatitis c.
EP3006037A1 (fr) 2011-04-01 2016-04-13 Novartis AG Traitement de l'infection par le virus de l'hepatite b, seul ou en combinaison avec le virus de l'hepatite delta et maladies du foie associees
AU2012241859A1 (en) 2011-04-13 2013-10-10 Debiopharm International Sa Treatment of Hepatitis C virus infection with alisporivir
EP2760461A1 (fr) 2011-09-27 2014-08-06 Novartis AG Alisporivir destiné au traitement d'une infection par le virus de l'hépatite c
SG11201406441RA (en) 2012-05-07 2014-11-27 Novartis Ag Pharmacokinetic modulation with alisporivir
CN104487449A (zh) 2012-06-01 2015-04-01 阿勒根公司 环孢菌素a类似物
WO2014085623A1 (fr) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Nouveaux analogues de [n-me-4-hydroxyleucine]-9-cyclosporine
WO2015008223A1 (fr) 2013-07-17 2015-01-22 Novartis Ag Traitement du virus de l'hépatite c avec l'alisporivir et la ribavirine
CN105579046A (zh) 2013-08-26 2016-05-11 英安塔制药有限公司 用于预防或治疗丙型肝炎的环孢菌素类似物
WO2015136455A1 (fr) 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2016112321A1 (fr) 2015-01-08 2016-07-14 Allergan, Inc. Dérivés de cyclosporine dans lesquels la chaîne latérale mebmt a été cyclisée

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DK0484281T4 (da) * 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
US5711944A (en) 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
KR100358922B1 (ko) 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US6214873B1 (en) 1997-04-04 2001-04-10 Welfide Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
ES2255275T3 (es) * 1998-07-01 2006-06-16 Debiopharm S.A. Nueva ciclosporina con perfil de actividad mejorado.
PL359411A1 (en) 2000-07-13 2004-08-23 Sankyo Company, Limited Amino alcohol derivatives
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002032447A2 (fr) * 2000-10-19 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Inhibiteur de degat cellulaire
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
DE60208355T2 (de) 2001-03-26 2006-07-27 Novartis Ag 2-amino-propanol derivate
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003029205A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
EP1470137B1 (fr) 2002-01-18 2009-09-02 Merck & Co., Inc. Agonistes du recepteur edg
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
NZ554412A (en) 2004-10-01 2011-01-28 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
WO2006071619A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc

Also Published As

Publication number Publication date
JP2007504260A (ja) 2007-03-01
AU2008203031A1 (en) 2008-07-31
PT1663287E (pt) 2009-09-03
KR101116968B1 (ko) 2012-03-14
NO20061479L (no) 2006-06-02
AU2004268382A1 (en) 2005-03-10
EP1797892B1 (fr) 2013-10-23
RU2006110533A (ru) 2007-10-10
DK1663287T3 (da) 2009-11-09
NZ545495A (en) 2010-01-29
SI1663287T1 (sl) 2009-10-31
DE602004022061D1 (de) 2009-08-27
JP4688806B2 (ja) 2011-05-25
HK1091732A1 (en) 2007-01-26
US20070275884A1 (en) 2007-11-29
IS2917B (is) 2014-12-15
SG149063A1 (en) 2009-01-29
ES2328361T3 (es) 2009-11-12
BRPI0414062A (pt) 2006-10-24
CN1842343A (zh) 2006-10-04
HRP20090535T1 (hr) 2009-11-30
PL1663287T3 (pl) 2009-12-31
BRPI0414062B8 (pt) 2021-05-25
CA2537137C (fr) 2013-05-28
US7968518B2 (en) 2011-06-28
AU2008203031B2 (en) 2011-04-07
IL173909A0 (en) 2006-07-05
TNSN06071A1 (en) 2007-10-03
EP1663287A1 (fr) 2006-06-07
GB0320638D0 (en) 2003-10-01
WO2005021028A1 (fr) 2005-03-10
EP1663287B1 (fr) 2009-07-15
CA2537137A1 (fr) 2005-03-10
IS8371A (is) 2006-03-24
KR20060132798A (ko) 2006-12-22
TWI342782B (en) 2011-06-01
MXPA06002394A (es) 2006-06-20
CY1110506T1 (el) 2015-04-29
TW200524626A (en) 2005-08-01
IL173909A (en) 2011-03-31
ZA200601550B (en) 2007-05-30
RU2389501C2 (ru) 2010-05-20
BRPI0414062B1 (pt) 2019-06-25
EP1797892A1 (fr) 2007-06-20

Similar Documents

Publication Publication Date Title
MA28032A1 (fr) Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
BR0114390A (pt) éteres de 7-desmetilrapamicina
MA28950B1 (fr) Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine
EP1838321A4 (fr) Antagonistes de cxcr4 pour le traitement de l'infection due au vih
MA26221A1 (fr) Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine.
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
BR0211986A (pt) 29-enóis de rapamicina
WO2002064096A3 (fr) Procedes d'utilisation d'agents antiviraux a base de pyrimidine
DE602004026053D1 (fr)
RU2012120343A (ru) Морфогенные белки кости (bmp), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы
EP2260845A3 (fr) Utilisation de polyphénol pour le traitement de l'alopécie
MA31666B1 (fr) Cyclic peptide cxcr4 antagonists
ATE296108T1 (de) Cyanovirin konjugate, matrix-verankertes cyanovirin und anti-cyanovirin antikörper, und verwandte zusammensetzungen und anwendungen
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
EP0932613A4 (fr) Blocage de l'expression de l'aggressine dans s. aureus
MA30865B1 (fr) Utilisation de cyclosporines modifiees
EP2322206A3 (fr) Nétrine 1 mutée, ses fragments et leur utilisation comme médicaments
WO2007030708A3 (fr) Adzymes antimicrobiens et leurs utilisations
EP2042188A4 (fr) Composition pharmaceutique destinée au traitement ou à la prévention d'une infection par le vhc